Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantSurvival RateCombined Modality TherapyAntineoplastic AgentsDisease-Free SurvivalTreatment OutcomeCisplatinRadiation DosageRadiation, IonizingSurvival AnalysisCyclophosphamideDoxorubicinCell SurvivalRadiation InjuriesNeoplasm StagingBreast NeoplasmsNeoadjuvant TherapyDose-Response Relationship, RadiationPrognosisRadiation ToleranceEtoposideLung NeoplasmsRadiationDrug Administration ScheduleNeoplasm Recurrence, LocalMethotrexateRadiotherapyCarboplatinRadiation ProtectionPaclitaxelTime FactorsFollow-Up StudiesNeoplasmsRadiation MonitoringVinblastineSurvivalInduction ChemotherapyTaxoidsDrug Resistance, NeoplasmRadiotherapy DosageKaplan-Meier EstimateRadiotherapy, AdjuvantBleomycinDeoxycytidineIfosfamideAntimetabolites, AntineoplasticAdenocarcinomaCarcinoma, Non-Small-Cell LungOrganoplatinum CompoundsNeoplasm MetastasisAntineoplastic Agents, AlkylatingBrain NeoplasmsSalvage TherapyOvarian NeoplasmsCytarabineAnthracyclinesProspective StudiesHodgkin DiseaseChemotherapy, Cancer, Regional PerfusionRadiation OncologyLymphoma, Non-HodgkinCell Line, TumorColorectal NeoplasmsTransplantation, AutologousAntineoplastic Agents, PhytogenicGraft SurvivalTesticular NeoplasmsDacarbazineTumor Markers, BiologicalNeutropeniaApoptosisCarcinoma, Squamous CellClinical Trials as TopicVomitingLiver NeoplasmsProportional Hazards ModelsNauseaBone NeoplasmsRadiation PneumonitisLymphatic MetastasisAntibiotics, AntineoplasticRecurrenceCarmustineRadiation Injuries, ExperimentalDose-Response Relationship, DrugLomustineMultivariate AnalysisCamptothecinNeoplasms, Germ Cell and EmbryonalDisease ProgressionChemoradiotherapyCarcinomaOsteosarcomaHead and Neck NeoplasmsPalliative CareNeoplasms, Radiation-InducedGranulocyte Colony-Stimulating FactorCosmic RadiationStomach Neoplasms